Biotech Outlook: Vertex and Mirum Target Rare Disease Markets

Vertex Pharmaceuticals (VRTX) and Mirum Pharmaceuticals (MIRM) are pursuing a similar growth strategy by focusing on high-unmet-need rare diseases. While Vertex maintains a stronghold in cystic fibrosis (CF), Mirum is aggressively expanding its footprint in cholestatic liver diseases. Mirum's financial trajectory is trending toward profitability. In 2025, the company reported revenue of $521.3 million, a 54% increase, driven largely by the $360 million generated from Livmarli. For 2026, the company forecasts product sales between $630 million and $650 million, while narrowing its annual earnings per share loss to $0.45 from $1.85 in 2024. The company recently completed an $820 million acquisition of Bluejay Therapeutics to acquire brelovitug, a potential treatment for chronic hepatitis delta virus (HDV). With an estimated 15 to 20 million patients worldwide, a successful launch could generate over $750 million in annual revenue. Key data readouts from the Vistas, Azure-1, and Azure-4 studies are expected throughout 2026. Simultaneously, Vertex continues to solidify its CF market share. On April 1, the FDA approved label extensions for Trikafta and Alyftrek, expanding access to 95% of U.S. patients with CF. This expansion allows the therapies to target a broader range of CFTR protein variants, regardless of the specific variant location. Market performance for the two firms has diverged recently, with Vertex shares down more than 2% and Mirum shares up over 20% year-to-date. Both companies remain positioned to benefit from their specialized focus on orphan drugs and strategic platform scaling.